2191-1991-2-18 2191-1991 Review <p>Methodological considerations in cost of illness studies on Alzheimer disease</p> CostaNagedecosta.n@chu-toulouse.fr DerumeauxHelenederumeaux.h@chu-toulouse.fr RappThomasthomas.rapp@parisdescartes.fr GarnaultValériegarnault.v@chu-toulouse.fr FerlicoqLauraferlicoq.l@chu-toulouse.fr GilletteSophiegillette.s@chu-toulouse.fr AndrieuSandrinesandrine.andrieu@univ-tlse3.fr VellasBrunovellas.b@chu-toulouse.fr LamureMichellamure@univ-lyon.fr GrandAlainalain.grand@univ-tlse3.fr MolinierLaurentmolinier.l@chu-toulouse.fr

Department of Medical Information, University Hospital of Toulouse, Toulouse, F-31059, France

UMR 1027, INSERM, Toulouse, F-31059, France

UMR 1027, University of Toulouse III, Toulouse, F-31059, France

Universty of Paris Descartes, Paris, 75016, France

Department of geriatric medicine, University hospital of Toulouse, Toulouse, F-31073, France

Department of Epidemiology and Public Health, University Hospital of Toulouse, Toulouse, F-31059, France

EDISS, University of Lyon I, Villeurbanne, F-69100, France

Health Economics Review 2191-1991 2012 2 1 18 http://www.healtheconomicsreview.com/content/2/1/18 10.1186/2191-1991-2-1822963680
56201227820121192012 2012Costa et al.; licensee Springer.This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Alzheimer disease Cost study Dementia Economic Evaluation Review

Abstract

Cost-of-illness studies (COI) can identify and measure all the costs of a particular disease, including the direct, indirect and intangible dimensions. They are intended to provide estimates about the economic impact of costly disease. Alzheimer disease (AD) is a relevant example to review cost of illness studies because of its costliness.The aim of this study was to review relevant published cost studies of AD to analyze the method used and to identify which dimension had to be improved from a methodological perspective. First, we described the key points of cost study methodology. Secondly, cost studies relating to AD were systematically reviewed, focussing on an analysis of the different methods used. The methodological choices of the studies were analysed using an analytical grid which contains the main methodological items of COI studies. Seventeen articles were retained. Depending on the studies, annual total costs per patient vary from $2,935 to $52, 954. The methods, data sources, and estimated cost categories in each study varied widely. The review showed that cost studies adopted different approaches to estimate costs of AD, reflecting a lack of consensus on the methodology of cost studies. To increase its credibility, closer agreement among researchers on the methodological principles of cost studies would be desirable.

Review

Introduction

Cost-of-Illness (COI) studies aim to identify and measure all the costs of a disease 1 . They describe and estimate the economic burden of a specific disease to a society, and therefore the savings that could be done if the disease were to be eradicated 2 . COI studies as decision making tool has been debated, but they may be useful by educating, informing and enlightening policy makers in planning and financing 3 . COI studies are particularly relevant in chronic diseases that weigh heavily on health expenditures. Dementia is characterized by a gradual and irreversible impairment of the intellect, memory, and personality. Alzheimer disease (AD) accounts for 60% to 80% of all dementia cases and its prevalence will increase with the life expectancy growth 4 . There are 35, 6 million demented people in 2011, increasing to 115,4 million by 2050 5 . Disease worldwide costs were US$ 604 billion in 2011, which 84% were attributable to informal and formal costs. COI studies are the initial step in an economic evaluation. Few cost-effectiveness analyses in AD drug treatment show divergent results in costs saving 6 7 , probably because of different methodologies. So, it is necessary to accurately assess AD costs to show the potential economic impact of new therapeutic or preventive strategies. Three articles were previously published on the methodology of AD costs 8 9 10 , but they were either focus on European studies including other dementia (not on AD specifically), or focus on informal costs and not focus on COI studies. This study aims to review relevant published AD COI studies, to analyze the methods used and to identify the points that should be improved in order to obtain convincing results from a methodological perspective. First, we provided a general description of the COI method. And then, we systematically reviewed AD costs studies, analyzing the different methods used.

Methods

Cost study

To conduct a COI study, it is necessary to define disease, epidemiological approach, type of costs, and study perspective. Subsequently, resource consumption data and unit costs can be gathered, and the results presented and methodically discussed, in conjunction with sensitivity analysis to test their robustness. A checklist (Table  1), containing its items, was developped on the model described by Drummond et al. 11 and adapted to COI by Molinier et al. 12 . An equal weight was given to each item. The final score was the sum of the eleven individual items.

<p>Table 1</p>

All studies

Lopez Bastida et al. 13

Coduras et al. 14

Rigaud et al. 15

Kronborg Andersen et al. 16

Cavallo et al. 17

Mesterton et al. 18

Kiencke et al. 19

Leon et al. 20

Hay et al. 21

Rice et al. 22

Leon et al. 23

Ostbye et al. 24

Zencir et al. 25

Wang et al. 26

Suh et al. 27

Beeri et al. 28

Allegri et al. 29

Total score by study was the sum of answers; P, Partially.

Yes

P

No

Yes

P

No

Yes

P

No

Yes

P

No

Yes

P

No

Yes

P

No

Yes

P

No

Yes

P

No

Yes

P

No

Yes

P

No

Yes

P

No

Yes

P

No

Yes

P

No

Yes

P

No

Yes

P

No

Yes

P

No

Yes

P

No

Yes

P

No

1 Was a clear definition of the illness given?

10

5

2

P

Yes

Yes

Yes

No

P

P

Yes

No

P

Yes

Yes

Yes

Yes

P

Yes

Yes

2 Were epidemiological sources carefully described?

13

3

1

Yes

Yes

Yes

Yes

Yes

P

Yes

Yes

Yes

Yes

P

Yes

P

Yes

Yes

No

Yes

3 Were costs sufficiently disaggregated ?

12

0

5

Yes

Yes

No

Yes

Yes

Yes

Yes

No

Yes

Yes

No

No

Yes

Yes

No

Yes

Yes

4 Were activity data sources carefully described?

15

1

1

Yes

Yes

Yes

Yes

Yes

Yes

P

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

Yes

Yes

5 Were activity data appropriately assessed?

6

9

2

Yes

P

P

P

P

Yes

No

Yes

Yes

Yes

P

No

P

P

Yes

P

P

6 Were the sources of all cost values analytically described?

10

4

3

Yes

Yes

Yes

Yes

P

Yes

No

Yes

Yes

P

P

No

P

Yes

Yes

No

Yes

7 Were unit costs appropriately valued?

7

5

5

Yes

Yes

P

P

P

Yes

No

Yes

Yes

P

No

No

No

Yes

Yes

No

P

8 Were the methods adopted carefully explained?

11

6

0

Yes

Yes

Yes

Yes

P

Yes

P

Yes

Yes

P

P

P

Yes

Yes

Yes

P

Yes

9 Were costs discounted ?

0

2

15

No

No

No

No

No

No

P

No

P

No

No

No

No

No

No

No

No

10 Were the major assumptions tested in a sensitivity analysis?

3

0

14

No

Yes

No

No

No

No

Yes

No

No

No

No

No

No

No

Yes

No

No

11 Was the presentation of study results consistent with the methodology of study?

13

4

0

Yes

Yes

Yes

Yes

Yes

Yes

Yes

P

P

Yes

Yes

P

Yes

Yes

Yes

P

Yes

12 Total score by study

100

39

48

8

1

2

9

1

1

6

2

3

7

2

2

4

4

3

7

2

2

4

4

3

7

1

3

7

2

2

5

4

2

3

4

4

2

2

7

5

3

3

8

1

2

8

1

2

3

3

5

7

2

2

Answers to the methodological questions by study

Defining the disease and population

Illness costs widely depend on how the disease is defined. AD diagnosis is based on Alzheimer’s Association criteria (NINCDS-ADRDA) 30 and Diagnostic and Statistical Manual of Mental Disorders criteria (DSM IV) 31 . As costs increase with disease severity 32 33 34 35 , disease stage must be specified and measured using validated tools, as Clinical Dementia Rate 36 (CDR) or Mini Mental State Examination (MMSE) 37 . Cost components may vary depending on the living conditions (e.g. home, institution), and therefore must be specified 33 38 .

Epidemiological approach

Prevalence-based COI studies estimate the economic burden to society during a period of time as a result of the prevalence of the disease (e.g. in a given year). Incidence-based studies estimate lifetime costs, and measure the costs of an illness from diagnosis until recovery or another endpoint (e.g. death).

Perspective of the analysis and costs assessed

A COI study may be conducted from several perspectives that must be specified to check that relevant costs are included. From the healthcare payer perspective, only direct costs incurred by a payer (e.g. national health insurance) are considered. Indirect costs and the patient “out-of-pocket” must also be included in a study which uses societal perspective.

Estimating resource consumption

Resource consumption estimates vary depending on the data available, but validated tools exist to collect them 39 . In prospective COI studies, events have not occurred yet, so data collection is done by the patients’ follow-up, medical records, data from clinical trials and patients or caregiver questionnaires. Conversely, in retrospective COI study, events have already occurred, so data collection must refer to recorded data, either using “Top-down” method (aggregate figures from hospital admissions, mortality, etc.) or “bottom-up” method (by referring to the patients sample record).

Valuation of unit costs

The COI is estimated by identifying the cost-generating components and by attributing them a monetary value. This is the opportunity cost, the value of the forgone opportunity to use in a different way those resources that are lost due to illness 11 . Direct and indirect costs should be valued to assess the total economic COI. Direct costs measure the resources used to treat an illness and can be estimated by per capita expenditures, national tariffs, market prices, and published studies. Patient charges and tariffs do not give an accurate estimate of the underlying costs. Market prices can be used to value some cost categories like drugs, rehabilitation items (e.g. eyeglasses, etc.). Direct costs can also be valued with care facilities estimates, through the analytical account system which specified distribution properties. Indirect costs measure the loss of productivity, the effect of the illness on the patient or caregiver abilities to work. Three methods are used to value indirect costs: the Human Capital Approach (HCA) 40 , the Friction Cost Method 41 and the Willingness to pay approach 42 . Informal care is an unpaid care often provided by relatives and plays a substantial role in the AD patient’s total care. Two methods are mainly used to value the shadow price of informal care time. The opportunity cost approach values the opportunity forgone as a result of caregiving and the replacement cost approach values the caregiving time spent at a price of a close substitute 9 43 44 .

Discounting costs

Discounting captures individual preferences for income today rather than income in the future and is frequently applied when COI studies are considered over several years. In the USA, they estimate the discount rate at 3% 45 . The following equation is applied to estimate costs:

C a = C t n = 1 t 1 + r n

Where: C a  = present value of cost strategy, C t  = value of cost strategy in year t, r = discount rate, t = time period.

Sensitivity analysis

Sensitivity analysis is recommended because COI studies contain uncertainties. It allows testing the robustness of the results by varying in range key variables (e.g., prevalence, unit costs, etc.) 46 . It seems more credible to present a range of possible illness costs.

Presentation of results

The presentation of COI results should be consistent with collected data and should disaggregate results into as many components as possible with full explanations given for clarity (Table  1).

Literature review

Study selection

A bibliographic search was performed on an international medical literature database (Medline). All studies which assessed the economic burden of AD were selected. To be exhaustive, eight keywords combinations were employed: “Alzheimer disease” AND “Cost of illness”; “Alzheimer disease” AND “Economic evaluation”; “Alzheimer disease” AND “Cost study”; “Alzheimer disease” AND “Cost analysis”; “Dementia” AND “Cost of illness”; “Dementia” AND “Economic evaluation”; “Dementia” AND “Cost study”; “Dementia” AND “Cost analysis”. This search provided us 2271 papers. We kept the 2033 papers written in English. Among them, we selected articles whose title contained “Dementia” or “Alzheimer disease” (801 papers were removed) AND “Costs” or “Expenses” or “Economic” or “Burden” (another 941 papers were removed). This study focused on the methodology used to estimate AD costs, 137 papers were removed because they were identified as global economic analyses. A hundred and fifty four abstracts were first selected and 46 of them underwent a subsequent full paper reading, thus providing 17 articles. Figure  1 illustrates the literature search, selection process, and presents reasons for excluded studies.

<p>Figure 1</p>

Literature search and selection process

Literature search and selection process.

Study review

A systematic review was performed. One author (N. Costa) selected abstracts. Six methodologists read the 46 papers retrieved by the search strategy and reviewed the 17 selected papers. With the key methodological points identified in the first part of the paper, they asked questions based on existing checklists for full economic evaluations 47 . The objective was not to establish a criteria hierarchy by using different weights, but to use these criteria to analyze the methods used. Each study was assessed separately by the reviewers. Finally, a consensus was reached by discussion. Then, all authors, both clinicians and methodologists, discussed the results.

Results

Seventeen studies met our criteria (Tables  2, 3). Seven studies were conducted in Europe 13 14 15 16 17 18 19 , 5 in North America 20 21 22 23 24 , 4 in Asia 25 26 27 28 and 1 in South America 29 . Fifteen studies selected a sample ranging in size from 42 to 21512 patients 13 14 15 16 17 18 19 20 22 23 24 25 26 27 28 29 .

<p>Table 2</p>

Study

Country

Type of helthcare system (insurance)

Year of valuation

Currency

Perspective

Design of cost analysis

Sample size

Type of setting

Follow-up (months)

Total annual cost per patient (US$)

NS: not specify; NA: not available, * Net Costs.

All costs are in US$ (1€ = 1,36491 US$, 1 CAN$ = 0,970458 US$, 1 DKK = 0,183360 US$, 1 RMB = 0,156987 US$; October 11, 2011) SEK, Swedish Crown; RMB, Yuan Renminbi; ₩, Won; $Ar, Argentine Peso; NIS, New Israeli Shekel; TRI, Turkish Lira; CAN$, Canadian Dollar; DKK, Danish Crown; €, Euro).

Lopez Bastida et al. 13

Spain

Public social

2001

Societal

Prosepective

237

At home

12

37,881

Coduras et al. 14

Spain

Public social

2006

Societal

Prospective multicentre

560

At home and in institution

12

22,558

Rigaud et al. 15

France

Public social

1996

Societal

Retrospective single centre

48

At home

6

31,153

Kronborg Andersen et al. 16

Denmark

Public social

1997

DKK

Societal

Prospective single centre

164

At home and in institution

12

17,078

Cavallo et al. 17

Italy

Public and private

1995

Family

Prospective single centre

423

At home

NS

52,954

Mesterton et al. 18

Sweden

Public social

2007

SEK

Societal

Prospective multicentre

233

At home and in institution

1

46,956

Kiencke et al. 19

Germany

Public health

2005

Healthcare payer

Decision model

21512

NS

60

11,786

Leon et al. 20

USA

Private

1996

US$

Societal

Prospective multicentre

150

At home and in institution

1

18,804

Hay et al. 21

USA

Private

1983

US$

Societal

Retrospective

NS

At home and in institution

Lifetime

18,517*

Rice et al. 22

USA

Private

1990

US$

Societal

Prospective multicentre

187

At home and in institution

12

51,905*

Leon et al. 23

USA

Private

1996

US$

Societal

Prospective multicentre

679

At home and in institution

NS

27,672

Ostbye et al. 24

Canada

Public social

1991

CAN$

Societal

Not specify

10263

At home and in institution

NS

13,900*

Zencir et al. 25

Turkey

Public and private

2003

TRY

NS

Prosepective

42

At home

3

3,492

Wang et al. 26

China

Public social insurance

2006

RMB

NS

Prospective single centre

66

NS

12

2,935*

Suh et al. 27

Korea

Private

2002

Societal

Decision model

NS

At home and in institution

12

11,389

Beeri et al. 28

Israel

Public social

1999

NIS

Societal

Prospective multicentre

121

At home and in institution

6

19,893*

Allegri et al. 29

Argentina

Public and private

2001

$Ar

Societal

Retrospective

100

At home and in institution

3

7,709

Cost of illness studie's characteristics in Alzheimer disease

<p>Table 3</p>

Study

Total annual cost per patient (US$)

Direct medical costs

Inpatient

Outpatient

Medication

Specialized institution

Other

Direct non medical costs

Home help

Nursing home

Transportation

Other

Informal costs

Indirect costs

NS: not specify; NA: not available, * Net Costs.

All costs are in US$ (1€ = 1,36491 US$, 1 CAN$ = 0,970458 US$, 1 DKK = 0,183360 US$, 1 RMB = 0,156987 US$; October 11, 2011).

SEK, Swedish Crown; RMB, Yuan Renminbi; ₩, Won; $Ar, Argentine Peso; NIS, New Israeli Shekel; TRI, Turkish Lira; CAN$, Canadian Dollar; DKK, Danish Crown; €, Euro).

Lopez Bastida et al. 13

37,881

4,848

924

844

2,468

301

311

2,306

2,223

NA

83

NA

29,884

843

Coduras et al. 14

22,558

4,744

144

503

2,137

1,97

NA

5,798

4,66

1,138

NA

NA

12,016

NA

Rigaud et al. 15

31,153

6,663

NS

NS

NS

NS

NA

5,632

5,632

NS

NS

NA

18,858

NA

Kronborg Andersen et al. 16

17,078

4,357

4,11

247

NA

NA

NA

12,721

12,663

NA

NA

58

NA

NA

Cavallo et al. 17

52,954

2,722

NA

NA

NA

2,722

NA

5,496

5,496

NA

NA

NA

44,736

NA

Mesterton et al. 18

46,956

3,155

1,067

1,118

970

NA

NA

39,373

6,487

32,886

NA

NA

4,428

NA

Kiencke et al. 19

11,786

11,786

2,889

1,449

2,126

NS

677

NA

NA

NA

NA

NA

NA

NA

Leon et al. 20

18,804

7,284

NS

NS

NS

NA

NA

NA

NA

NA

NA

NA

11,52

NA

Hay et al. 21

18,517*

2,292

756

1,292

244

NA

NA

7,285

1,774

5,326

167

18

9

NA

Rice et al. 22

51,905*

22,176

1,072

545

301

19,521

737

9,699

9,585

NA

NA

114

20,03

NA

Leon et al. 23

27,672

21,924

NS

NS

NS

NS

NS

NA

NA

NA

NA

NA

5,748

NA

Ostbye et al. 24

13,900*

NS

NS

NS

NS

NS

NS

NS

NS

NS

NA

NS

NS

NA

Zencir et al. 25

3,492

2,128

NA

37

2091

NA

NA

NA

NA

NA

NA

NA

1,364

NA

Wang et al. 26

2,935*

863

29

32

802

NA

11

431

373

NA

NA

27

1,63

NA

Suh et al. 27

11,389

4,394

NS

NS

NS

NA

NA

445

445

NA

NA

NA

6,55

NA

Beeri et al. 28

19,893*

3,974

1,749

1,63

584

NA

11

9,326

1,822

7,504

NA

NA

6,593

NA

Allegri et al. 29

7,709

3,389

525

280

2,389

NA

195

2,488

187

2,301

NA

NA

1,832

NA

Total annual costs disaggregation

Defining the disease and population

AD was defined with NINCDS-ADRDA criteria for 4 studies 20 23 28 29 , with DSM criteria for 2 studies 25 26 , with both criteria for 4 studies 14 15 16 24 and with ICD-10 for another study 19 . Six studies did not specify the criteria used 13 17 18 21 22 27 . Disease severity was measured with MMSE in 9 studies 14 15 18 22 24 25 26 27 28 , with CDR in 3 studies 13 16 23 , and with both tests for 2 studies 20 29 . Disease severity was not specified in three studies 17 21 23 . Four studies included community dwelling patients 13 15 17 25 and 11 studies included both patients in community and in institution 14 16 18 20 21 22 23 24 27 28 29 . The place of living was not specified in 2 studies 19 26 .

Thirteen studies specified the mean age of the sample of patients ranging from 70,5 to 81,8 years 13 14 15 16 17 18 19 20 22 25 26 28 29 .Two studies included patients aged from 50 to over 80 years 21 24 .

Perspective of the analysis and costs assessed

The adopted perspective was the society in 13 studies 13 14 15 16 18 20 21 22 23 24 27 28 29 and respectively the family and the healthcare payer in two studies 17 19 . Fourteen studies quantified direct medical and non-medical costs and informal costs 14 15 17 18 20 21 22 23 24 25 26 27 28 29 . Two studies did not include inpatient costs 17 25 . Informal costs were defined as direct non-medical costs in seven studies 14 15 17 19 22 23 25 and as indirect costs in seven studies 18 21 24 26 27 28 29 . One study quantified all the costs (i.e. direct, informal and indirect) 13 , indirect costs were defined as patient early retirement and informal costs as direct non-medical costs. Danish study quantified only direct medical and non-medical costs 16 . German study quantified only direct medical costs 19 .

Estimating resource consumption

Three studies estimated resource consumption retrospectively 15 21 29 . Two of them used bottom-up approach to gather activity data through questionnaires 15 29 . The other used a top-down approach, using published national indicators, national surveys and published studies 21 . Eleven studies estimated resource consumption prospectively 13 14 16 17 18 20 22 23 24 26 28 . Two studies used mainly the Resource Utilisation in Dementia (RUD) 48 to gather activity data 14 18 , completed with report forms, medical records and questionnaires on 560 patients in the Spanish study 14 . Nine studies gathered activity data mainly with questionnaires 13 16 17 20 22 23 25 26 28 . In the Danish study, 164 AD couple (i.e. patients/caregivers) was interviewed at home about Activities of Daily Living (ADL), use of health care and community services 16 . Two US studies measured direct costs using caregiver’s interviews and Medicare Current Beneficiary Survey (MCBS) 13 23 . Rice et al. gathered activity data through monthly caregiver’s telephone interviews, billing records and with calendar given to caregiver at the baseline visit 23 . Israeli study used a baseline questionnaire to record time spent on caring and use of goods and services, and secondly recorded the same items with 5 monthly telephone interviews 28 . Two studies recorded data via mailed questionnaires filled out by caregivers 13 17 . Turkish study used a questionnaire and daily time sheets for caregiving time 25 . Wang et al. interviewed 66 AD couples for filling out the resource use’s questionnaire 26 . Two studies used decision modelling 19 27 and estimated resources with published sources and national surveys 27 or with data extractions of a German retrospective analysis 19 . One study did not precise the approach used to gather activity data 24 . Eight studies specified the number of caregiver included, several for 4 studies 13 15 17 22 and only one for others 18 23 25 28 . Eight studies recorded AD net costs 15 16 21 22 24 26 28 29 either by subtracting healthy patient costs or by asking AD couple about resource’s used exclusively for AD.

The follow-up period was the lifetime in the study which adopted the incidence-based approach 21 and was one year in six studies 13 14 16 22 26 27 , but was frequently reduced to six, three or one month 14 18 20 25 28 29 . One study used a sixty months follow-up period 19 .

Valuation of unit costs

Direct costs were estimated from published data, national estimates and Medicare-over charges in one American study 21 , and from unit costs using the MCBS and national estimates for adult day care in another one 20 . Rice et al. used charges and bills provided by the caregivers 22 . Two Spanish studies used the Spanish database on medical costs (SOIKOS), patient’s reports and the Spanish Vademecum to estimate unit costs 13 14 . Direct unit costs were based on reimbursement tariffs used by the French social health insurance and on the French Disease related group (DRG) for inpatient care 15 . The Danish study used the reimbursement tariffs of social insurance, hospital accounts, gross wage rates of professionals and amortization procedure to value direct costs 16 . Institutional costs were valued with the average cost per day without food and beverage. Zencir et al. valued unit costs with the average price of public and private physician visits and with the average price per day for medication 25 . In the Chinese study, unit costs were valued with drugs prices, transportation reimbursements and local fees for home help 26 . Tariffs of social health insurance and full drugstore prices were used to unit costs valuation in the Argentinian study 28 . Meserton et al. valued unit costs with ward-specific per diem costs from regional price, the lowest available price for medication and with per visit costs 21 . For residential care, the number of days in institution was multiplied by the corresponding unit costs. Two studies used national estimates to value unit costs 23 27 . No information relating to direct costs valuation was reported in four studies 17 18 19 24 . Twelve studies used the replacement cost approach to value informal care 13 15 17 20 21 22 23 24 25 26 28 29 . Seven studies used national estimates of a close substitute 17 20 21 22 23 25 29 . Among these, 5 studies used different national wages to value different caregiver’s activities 17 20 22 23 28 . Israeli study obtained different hourly wage rates for each activity from the Central Bureau of Statistics 28 and Leon et al. used hourly wage of home health aids to value ADL time and homemaker’s hourly wage to value IADL time 23 . Two studies used hospital nurse hourly wage 21 25 , another one, local wage rate without specifying the type of professional caregiver 26 and the Canadian study used published data 24 . Three studies did not specify the sources used to value informal care time 13 15 29 . Nevertheless, one study used professional caregiver monthly salary 29 , another the cost per hour of a domestic cleaner gross wage 13 and the last one the average between housekeeping and paid assistance wage 15 . One study chose opportunity cost approach to value informal care, using the mean informal caregiver own salary 14 . Both approaches were used in one study 27 . The time spent by working caregivers was valued with national estimates and the time spent by working caregivers was valued with the own caregivers salaries. Opportunity cost and revealed preference approaches were used to value informal costs in one study 18 . Caregiving time was valued either with the HCA (working caregivers) or with a monetary estimate value of one hour of leisure time (not working caregivers). One study valued indirect costs with national estimates on employment and wages 13 .

Discounting costs

One study has discounted costs without specifying the discounting rate 21 . German study performed costs discounting in the sensitivity analysis 19 . All the other studies used a short follow-up period and had no need to discount costs.

Sensitivity analysis

Only three studies performed a sensitivity analysis 14 27 29 . One study analyzed the impact of informal costs variation 14 , another one the variation of AD sufferers’ proportion according to the need of full time care level 27 , and the last one the discounting of the incurred costs 19 .

Presentation of results

Most studies presented their results clearly. They were mainly well explained and consistently set out in relation to the methods adopted. Five studies did not sufficiently disaggregate costs, so the information strength was reduced (Table  3) 15 20 23 24 27 . All studies presented results in terms of cost per patient. Four studies proposed also AD total costs for the country 13 23 24 27 . According to the key methodological points, we have drafted a checklist of questions related to the eight items analyzed (Table  1). For 9 studies, the answers of at least seven to eleven questions were “yes” 13 14 16 18 20 21 26 27 29 .

Conclusion

This study reviewed seventeen COI studies on AD with the main goal of analyzing the various methodologies. According to the key methodological points, nine studies scored “yes” on the majority of the questions 13 14 16 18 19 21 26 27 29 .

In this review, annual cost per patient varies from $2,935 to $52,954, confirming the costly character of AD. Nevertheless, commenting on these quantitative results is a problem because different approaches have been adopted. Informal care time varies widely according to the tool used. Validated instruments such as RUD, Caregiver Activity Survey (CAS) or Caregiver Activity Time Survey (CATS) exist to estimate informal care time 48 49 50 . Most often, time spent in ADL and IADL was used but they measure dependence and not specifically AD caregiving time. Opportunity cost underestimates the time of women, elderly and minority that suffer from discrimination in labour market 51 , and does not allow the valuation of different informal caregiving activities. These activities change can be considered with the replacement cost approach. Informal costs vary with the number of caregiver included. Informal costs can be 8 times higher if several caregivers are included rather than just one. AD informal costs have to be rigorously quantified because they represent 36% to 85% of total costs 9 .

Unlike clinical trial results, it is very difficult to generalize results of economic studies conducted in different countries. Economic results are difficult to compare because of monetary issues (i.e. fluctuating exchange rates, purchasing powers of currencies). According to the World Bank classification 52 , 3 studies in this review were conducted in upper middle income economies 25 26 29 and presented a mean annual cost for an AD patients which is 5 times lower than in studies conducted in high income economies. Purchasing Power Parity (PPP) use could help results comparison because it eliminates price levels differences between countries 53 .

Domestic characteristics also affect resource consumption and unit costs, including differences in clinical practice and healthcare system framework. For example, medication costs can vary between studies because of the use of tariffs in solidarity systems which are not comparable to free prices in private systems.

Follow-up periods found in this review were often less than one year, which is a short period to assess chronic disease costs. However, data collection over a long period is difficult so the use of models could compensate this difficulty.

Some limitations are present in this review as only English papers were selected, which restricted our sample. Another limitation is based on the lack of items weighting (Table  1). It is likely that results are more significantly affected by some items than others. Further works must be performed in this area.

Nevertheless, this study built an inventory on the methodology used to analyze AD costs and helped in better understanding the reasons of disparate results between studies.

COI results are the basis for economic evaluations and provide information for models that is a part of any efficiency evaluation 45 . Nevertheless, an insufficient description of methods may lead to misunderstandings. COI studies identified in this review highlight the poor consensus of methodological approaches. Medical journal should encourage researchers to give clear descriptions and discuss limitations, and a further effort should be made to validate methodology. The definition of standards, with a large consensus in the methodology selected to conduct this studies, should be a major concern for the scientific community. A collective awareness about disease burden exists between economists, policies and caregivers that may lead to relevant decision making. COI studies can serve as a basis for projecting disease expenses, and thus allow adapting medical and social disease management in order to control AD costs.

Abbreviations

AD: Alzheimer disease; ADL: Activity of Daily Living; CAS: Caregiver Activity Survey; CATS: Caregiver Activity Time survey; COI: Cost of illness study; CDR: Clinical Dementia Rate; DSM: Diagnostic and Statistical Manual of Mental Disorders; DRG: Disease Related Group; HCA: Human Capital Approach; IADL: Instrumental Activity of Daily Living; MCBS: Medicare Current Beneficiary Survey; MMSE: Mini Mental State Examination; N: No; NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association; NA: Not Applicable; NS: Not Specified; NM: Not Measured; MNS: Measured but Not Specified; P: Partially; PPP: Purchasing Power Parity; RUD: Resource Utilization in Dementia; Y: Yes.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

NC supervised the project and its implementation, conducted the literature review, drafted the article and approved his final version. LM designed the study and helped supervise the project and its implementation, conducted the literature review, drafted the article and approved his final version. HD and TR helped to implement the project, conducted the literature review, reviewed the article and approved final version.VG and LF helped conduct the literature review, reviewed the article and approved his final version. SG, SA, ML, AG and BV helped the interpretation of data, reviewed the article and approved his final version. All authors read and approved the final manuscript.

Financial support

This study was supported by a grant from the French Ministry of Health (PHRCN 2008, 08 111 01).

Acknowledgements

We gratefully acknowledge B. Giachetto for assistance.

<p>Cost of illness studies</p>ByfordSTorgersonDJRafteryJBMJ2000320133510.1136/bmj.320.7245.1335112732010807635<p>Cost of illness studies: Useful for health policy?</p>KoopmanschapMAPharmacoEconomics199814214314810.2165/00019053-199814020-0000110186453<p>Annual costs of illness versus Lifetime costs of illness and implications of structural change</p>HogdsonTADrug Inf J198822323341<p>2011 Alzheimer's disease facts and figures</p>Alzheimer’s Association ReportsW V Med J20111073828321702424<p>World Alzheimer Report 2011, The global Economic Impact of Dementia</p>WimoAPrinceMAlzheimer Disease Int2010152<p>Economic evaluation of donepezil for the treatment of Alzheimer’s disease in Canada</p>O’BrienBJGoereeRHuxMIskedjianMBlackhouseGGagnonMGauthierSJournal Am Gerriatr soc1999475570578<p>The effect of donepezil therapy on health costs in a Medicare managed plan</p>HillJWFuttermanRMasteyVFillitHManag Care Interface2002153637012143299<p>The cost of dementia in Europe: a review of the evidence, and methodological considerations</p>JönssonLWimoAPharmacoEconomics200927539140310.2165/00019053-200927050-0000419586077<p>A review of the methods used to estimate the cost of Alzheimer's disease in the United States</p>MauskopfJMuchaLAm J Alzheimers Dis Other Demen201126429830910.1177/153331751140748121561991<p>Estimating the costs of informal care for people with Alzheimer's disease: methodological and practical challenges</p>McDaidDInt J Geriatr Psychiatry200116440040510.1002/gps.35311333428DrummondMFMethods for the economic evaluation of health care programmesOxford: Oxford University Press32005<p>Methodological considerations in cost of prostate cancer studies: a systematic review</p>MolinierLBauvinECombescureCCastelliCRebillardXSouliéMDaurèsJPGrosclaudePValue Health200811587888510.1111/j.1524-4733.2008.00327.x18494749<p>Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain</p>Lopez-BastidaJSerrano-AguilarPPerestelo-PerezLOliva-MorenoJNeurology200626;67122186219123269599<p>Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study</p>CodurasARabasaIFrankABermejo-ParejaFLópez-PousaSLópez-ArrietaJMDel LlanoJLeónTRejasJJ Alzheimers Dis201019260161520110605<p>Patients with Alzheimer's disease living at home in France: costs and consequences of the disease</p>RigaudASFagnaniFBayleCLatourFTraykovLForetteFJ Geriatr Psychiatry Neuro200316314014510.1177/0891988703252558<p>The cost of dementia in Denmark: the Odense Study</p>Kronborg AndersenCSøgaardJHansenEKragh-SørensenAHastrupLAndersenJAndersenKLolkANielsenHKragh-SørensenPDement Geriatr Cogn Disord199910429530410.1159/00001713510364648<p>The economic and social burden of Alzheimer disease on families in the Lombardy region of Italy</p>CavalloMCFattoreGAlzheimer Dis Assoc Disord19971141841909437435<p>Cross sectional observational study on the societal costs of Alzheimer's disease</p>MestertonJWimoAByALangworthSWinbladBJönssonLCurr Alzheimer Res20107435836710.2174/15672051079116243019939223<p>Direct costs of Alzheimer disease in Germany</p>KienckePDietmarDGrimmCRychlikREur J Health Econ20111253353910.1007/s10198-010-0267-x20640868<p>The cost of Alzheimer's disease in managed care: a cross-sectional study</p>LeonJNeumannPJAm J Manag Care19995786787710557408<p>The economic costs of Alzheimer's disease</p>HayJWErnstRLAm J Public Health19877791169117510.2105/AJPH.77.9.116916470163113273<p>The economic burden of Alzheimer's disease care</p>RiceDPFoxPJMaxWWebberPALindemanDAHauckWWSeguraEHealth Aff199312216417610.1377/hlthaff.12.2.164<p>Alzheimer's disease care: costs and potential savings</p>LeonJChengCKNeumannPJHealth Aff199817620621610.1377/hlthaff.17.6.206<p>Net economic costs of dementia in Canada</p>OstbyeTCrosseECMAJ199415;151101457146423228999<p>Cost of Alzheimer's disease in a developing country setting</p>ZencirMKuzuNBeşerNGErginACatakBSahinerTInt J Geriatr Psychiatry200520761662210.1002/gps.133216021668<p>Economic impact of dementia in developing countries: an evaluation of Alzheimer-type dementia in Shanghai, China</p>WangGChengQZhangSBaiLZengJCuiPJZhangTSunZKRenRJDengYLXuWWangYChenSDJ Alzheimers Dis200815110911518780971<p>The economic costs of dementia in Korea, 2002</p>SuhGHKnappMKangCJInt J Geriatr Psychiatry200621872272810.1002/gps.155216858741<p>Economic cost of Alzheimer disease in Israel</p>BeeriMSWernerPAdarZDavidsonMNoySAlzheimer Dis Assoc Disord2002162738010.1097/00002093-200204000-0000412040302<p>Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina</p>AllegriRFButmanJArizagaRLMachnickiGSerranoCTaraganoFESarasolaDLonLInt Psychogeriatr200719470571810.1017/S104161020600378416870037<p>Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease</p>McKhannGDrachmanDFolsteinMKatzmanRPriceDStadlanEMNeurology198434793994410.1212/WNL.34.7.9396610841<p>Diagnostic and Statistical Manual of Mental disorders</p>American Psychiatric AssociationWashington DC: American Psychiatric Association42000<p>Cost of illness studies of dementia: a systematic review focusing on stage dependency of costs</p>QuentinWRiedel-HellerSLuppaMRudolphAKönigHHActa Psyciatra Scandinavia201012124325910.1111/j.1600-0447.2009.01461.x<p>The impact of symptom severity on the cost of Alzheimer disease</p>SmallGWMcDonnellDDBrooksRLPapadopoulosGJournal American Geriatric society200250232132710.1046/j.1532-5415.2002.50065.x<p>Alzheimer’s disease: the strength of association of costs with different measures of disease severity</p>MauskopfJRacketaJSherrillEJ Nutr Health Aging201014865566310.1007/s12603-010-0312-620922342<p>Canadian Outcomes Study in Dementia [COSID] Investigators, The relation between disease severity and cost of caring for patients with Alzheimer disease in Canada</p>HermanNTamDYBalshawRSambrookRLesnikovaNLanctôtKLCan J Psychiatry2010551276877521172097<p>The Clinical Dementia Rating [CDR]: current version and scoring rules</p>MorrisJCNeurology19834324122414<p>Population-based norms for the mini-mental state examination by age and educational level</p>CrumRMAnthonyJCBassettSSFolsteinMFJAMA19932692386238910.1001/jama.1993.035001800780388479064<p>Longitudinal study of effects on patient characteristics on direct costs in Alzheimer disease</p>ZhuCWScarmeasNTorganRAlbertMBrandtJBlackerDSanoMSternYNeurology2006676998100510.1212/01.wnl.0000230160.13272.1b16914696<p>Cost of illness analysis. What room in health economics</p>TarriconeRHealth Policy200677516310.1016/j.healthpol.2005.07.01616139925<p>Indirect costs in economic studies: confronting the confusion</p>KoopmanschapMARuttenFFPharmacoEconomics1993444645410.2165/00019053-199304060-0000610146911<p>Towards a new approach for estimating costs of disease</p>KoopmanschapMAvan IneveldBMSoc Sci Med19923491005101010.1016/0277-9536(92)90131-91631600<p>Cost of illness methodology a guide to current practices and procedures</p>HogdsonTAMeinersMRMilbank Mem Fund Q Health Soc198260342946210.2307/33498016923138<p>Economic valuation of informal care: lessons from the application of the opportunity costs and proxy goods methods</p>Van der BergBBrouwerWVan ExelJKoopmanschapMVan den BosGAMRuttenFSoc Sci Med20066283584510.1016/j.socscimed.2005.06.04616137814<p>An overwiew of methods and application to value informal care in economic evaluation of healthcare</p>KoopmanschapMAVan ExelJNVan den BergBBrouwerWBPharmacoEconomics200826426928010.2165/00019053-200826040-0000118370563<p>Cost effectiveness in Health and Medicine</p>GoldMRRusselLBSiegelJEDanielsNWeinsteinMCJAMA1996276141172117710.1001/jama.1996.035401400600288827972<p>Sensitivity analysis in health economic and pharmacoeconomic studies. An appraisal of the literature</p>AgroKEBradleyCAMittmannNPharmacoeconomics199711758810.2165/00019053-199711010-0000910165529<p>Burden of illness estimates for priority setting: a debate revisited</p>WisemanVMooneyGHealth Policy19984324325110.1016/S0168-8510(98)00003-710178574<p>Assessment of informal services to demented people with the RUD instrument</p>WimoANordbergGJanssonWGrafströmMInt J Geriatr Psychiatry2000151096997110.1002/1099-1166(200010)15:10<969::AID-GPS272>3.0.CO;2-911044880<p>The Caregiver Activity Survey [CAS]: development and validation of a new measure for caregivers of persons with Alzheimer's disease</p>DavisKLMarinDBKaneRPatrickDPeskindERRaskindMAPuderKLInt J Geriatr Psychiatry1997121097898810.1002/(SICI)1099-1166(199710)12:10<978::AID-GPS659>3.0.CO;2-19395929<p>Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease</p>ClippECMooreMJClin Pharmacol Ther199558222823610.1016/0009-9236(95)90201-57648773SegelJECost-of-Illness studies-A primerRTI international <p>RTI -UNC Center of Excellence in Health Promotion Economics</p> 2006139 http://www.rti.org/pubs/coi_primer.pdf World BankWorld Bank -list economies.Country and lending groups2011http://data.worldbank.org/about/country-classifications/country-and-lendinggroups#Upper_middle_income 1. (Accessed October 26, 2011)<p>Purchasing power parities: measurement and uses. Statistics breaf</p>SchreyerPKoechlinFOECD Statistics brief2002318